<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081765</url>
  </required_header>
  <id_info>
    <org_study_id>697/20</org_study_id>
    <nct_id>NCT05081765</nct_id>
  </id_info>
  <brief_title>The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib</brief_title>
  <official_title>The Effect of Glucose Level and Diabetes Mellitus on the Plasma Minimum Steady-state Concentration Ctrough of Olaparib in Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Poznan University Hospital of Lord's Transfiguration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monitored therapy of olaparib concentrations in the blood of diabetic population probably&#xD;
      will assess the need for individual dosing of the drug.&#xD;
&#xD;
      The project concerns on the monitored therapy of olaparib in a population of patients with&#xD;
      DM, hyperglycemia and normal glucose level.&#xD;
&#xD;
      Currently, there are no studies assessing the effect of comorbidities and of the administered&#xD;
      drugs on the pharmacokinetics of olaparib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research is conducted at the Poznan University of Medical Sciences, and the Poznan,&#xD;
      Poland with the approval from the Bioethics Committee, University of Medical Sciences,&#xD;
      Poznan, Poland (697/20). The subjects of the research: the C through of olaparib in the&#xD;
      patients with ovarian cancer who received olaparib The patients included in the study if they&#xD;
      met the following criteria: treatment with olaparib above four days, age &gt;18 years; no&#xD;
      history of allergy to olaparib. The chief criteria for exclusion included allergy to&#xD;
      olaparib, age under 18 years, status of the patient which do not allowed the patient to&#xD;
      continue the study.&#xD;
&#xD;
      Administration and blood sampling The patients with an ovarian cancer treated with olaparib&#xD;
      (tablets in dose 300mg/12h, 250mg/12h, 200 mg/12h or capsules 400mg/12h, 200mg/12h, 100&#xD;
      mg/12h).&#xD;
&#xD;
      Blood samples (2 mL) collected at steady state before morning drug administration. The blood&#xD;
      samples transferred into heparinised tubes and centrifuged at 2880 g for 10 min at 4 °C. Next&#xD;
      the plasma transferred to propylene tubes and stored at - 20 °C until analysis.&#xD;
&#xD;
      Assays The concentrations of olaparib in plasma assayed using the high-performance liquid&#xD;
      chromatography (HPLC) method with ultraviolet (UV) detection. The method validated according&#xD;
      to European Medicines Agency guideline. The method validation confirmed good precision (CV%&#xD;
      &lt;15%), accuracy (92.3-115.0%) and linearity (r=0.9994) in the range of 100-4000 ng/mL.&#xD;
&#xD;
      The severity of olaparib adverse effects assessed by CTCAE (Common Terminology Criteria for&#xD;
      Adverse Events) v.5.0 scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>correlation between glucose level and C through.olaparib in the blood of the patients with ovarian cancer</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>There is idea to check the correlation of C through of the olaparib taken by the patients with diabetes melitus and ovarian cancer and the correlation of C through and glucose of the patients with hyperglycemia diagnosed during olaparib treatment</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovary Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with diabetes mellitus</arm_group_label>
    <description>olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with hyperglycemia,</arm_group_label>
    <description>olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with normal glucose level</arm_group_label>
    <description>olaparib 2 x 300mg /24h tablets = olaparib 2 x 400mg/24 olaparib 2 x 250mg/24h tablets = olaparib 2 x 200mg/24h olaparib 2 x 200mg/24h tablets = olaparib 2 x 100mg/24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)</intervention_name>
    <description>correlation between C through and taken drug</description>
    <arm_group_label>Patient with normal glucose level</arm_group_label>
    <arm_group_label>Patients with diabetes mellitus</arm_group_label>
    <arm_group_label>Patients with hyperglycemia,</arm_group_label>
    <other_name>olaparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lynparza</intervention_name>
    <description>correlation between C through and taken drug</description>
    <arm_group_label>Patient with normal glucose level</arm_group_label>
    <arm_group_label>Patients with diabetes mellitus</arm_group_label>
    <arm_group_label>Patients with hyperglycemia,</arm_group_label>
    <other_name>olaparib</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The probe with blood taken to check the C through of olaparib&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects of the research are patients with ovarian cancer who received olaparib as a&#xD;
        maintance therapy after platin basen chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ovarian cancer patients treated with olaparib above than 4 days&#xD;
&#xD;
          -  patient who gave permission to take part in the trial&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  no history of allergy to olaparib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to olaparib,&#xD;
&#xD;
          -  age under 18 years,&#xD;
&#xD;
          -  status of the patient which do not allowed the patient to continue the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna J Stanisławiak - Rudowicz</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medical Sciences Poznań, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna i Stanislawiak-Rudowicz, MD, PhD</last_name>
    <phone>0048605781967</phone>
    <email>stanisl@interia.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edyta Szałek, Prof</last_name>
    <phone>0048604773994</phone>
    <email>szalekedyta@wp.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University od Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Stanislawiak-Rudowicz, MD,PhD</last_name>
      <phone>0048605781967</phone>
      <email>stanisl@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Joanna Stanislawiak-Rudowicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edyta Szalek, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_pl.pdf</url>
    <description>Summary of product characteristic</description>
  </link>
  <link>
    <url>https://journals.viamedica.pl/onkologia_w_praktyce_klin_edu/article/view/58916</url>
    <description>Onkol Prakt Klin Edu 2018;4(3):167-178.</description>
  </link>
  <reference>
    <citation>Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P. [PARP inhibitors--theoretical basis and clinical application]. Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.</citation>
    <PMID>22706117</PMID>
  </reference>
  <reference>
    <citation>Wiśnik E, Ryksa M, Koter-Michalak M. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective]. Postepy Hig Med Dosw (Online). 2016 Apr 13;70:280-94. Review. Polish.</citation>
    <PMID>27117104</PMID>
  </reference>
  <reference>
    <citation>Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31. Erratum in: Lancet Oncol. 2015 Apr;16(4):e158.</citation>
    <PMID>24882434</PMID>
  </reference>
  <reference>
    <citation>Friedlander M, Banerjee S, Mileshkin L, Scott C, Shannon C, Goh J. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. Asia Pac J Clin Oncol. 2016 Dec;12(4):323-331. doi: 10.1111/ajco.12636. Review. Erratum in: Asia Pac J Clin Oncol. 2017 Aug;13(4):337.</citation>
    <PMID>27917619</PMID>
  </reference>
  <reference>
    <citation>Szałek E, Karbownik A, Sobańska K, Grabowski T, Połom W, Lewandowska M, Wolc A, Matuszewski M, Grześkowiak E. The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. Pharmacol Rep. 2014 Oct;66(5):892-6. doi: 10.1016/j.pharep.2014.05.011. Epub 2014 Jun 6.</citation>
    <PMID>25149997</PMID>
  </reference>
  <reference>
    <citation>Karbownik A, Szałek E, Sobańska K, Grabowski T, Wolc A, Grześkowiak E. The alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbits. Pharmacol Rep. 2016 Oct;68(5):964-8. doi: 10.1016/j.pharep.2016.04.015. Epub 2016 May 6.</citation>
    <PMID>27372922</PMID>
  </reference>
  <reference>
    <citation>Dostalek M, Court MH, Yan B, Akhlaghi F. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol. 2011 Jul;163(5):937-47. doi: 10.1111/j.1476-5381.2011.01270.x.</citation>
    <PMID>21323901</PMID>
  </reference>
  <reference>
    <citation>Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012 Aug 1;51(8):481-99. doi: 10.2165/11631900-000000000-00000. Review.</citation>
    <PMID>22668340</PMID>
  </reference>
  <reference>
    <citation>Tran M, Elbarbry F. Influence of diabetes mellitus on pharmacokinetics of drugs. MOJ Bioequiv Availab. 2016;2(1):3-4.</citation>
  </reference>
  <reference>
    <citation>Porażka J, Szałek E, Połom W, Czajkowski M, Grabowski T, Matuszewski M, Grześkowiak E. Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration. Eur J Drug Metab Pharmacokinet. 2019 Aug;44(4):579-584. doi: 10.1007/s13318-019-00543-1.</citation>
    <PMID>30778911</PMID>
  </reference>
  <reference>
    <citation>Stachowiak A, Szałek E, Karbownik A, Łojko A, Porażka J, Przewoźna I, Grabowski T, Wolc A, Grześkowiak E. The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of Paracetamol in Patients with Febrile Neutropenia. Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):289-294. doi: 10.1007/s13318-018-0508-4.</citation>
    <PMID>30187443</PMID>
  </reference>
  <reference>
    <citation>Karbownik A, Szałek E, Sobańska K, Klupczynska A, Plewa S, Grabowski T, Wolc A, Moch M, Kokot ZJ, Grześkowiak E. A pharmacokinetic study on lapatinib in type 2 diabetic rats. Pharmacol Rep. 2018 Apr;70(2):191-195. doi: 10.1016/j.pharep.2017.09.003. Epub 2017 Sep 18.</citation>
    <PMID>29471066</PMID>
  </reference>
  <reference>
    <citation>Karbownik A, Stachowiak A, Urjasz H, Sobańska K, Szczecińska A, Grabowski T, Stanisławiak-Rudowicz J, Wolc A, Grześkowiak E, Szałek E. The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats. Pharmacol Rep. 2020 Feb;72(1):254-259. doi: 10.1007/s43440-019-00021-0. Epub 2020 Jan 8. Erratum in: Pharmacol Rep. 2021 Oct;73(5):1483.</citation>
    <PMID>32016844</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Stanisławiak-Rudowicz Joanna</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Doctor</investigator_title>
  </responsible_party>
  <keyword>olaparib</keyword>
  <keyword>blood-level testing</keyword>
  <keyword>C through</keyword>
  <keyword>diabetes melitus</keyword>
  <keyword>hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To check C through of olaparib and morphology, Alat, Aspat and GFR and glucose level</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

